Work

Targeting hepatic glucokinase to treat diabetes with TTP399, a hepatoselective glucokinase activator

Year: 2019

Type: article

Source: Science Translational Medicine

DOI: 10.1126/scitranslmed.aau3441

Authors: Adrian Vella, Jennifer L. R. Freeman, Imogene Dunn, Kit Keller, John B. Buse, Carmen Valcarce

Institutions: Mayo Clinic, vTv Therapeutics (United States), University of North Carolina at Chapel Hill

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2909977372

FWCI: 6.37

Cites: 47

Cited by: 74

Related to: 10